POST Online Media Lite Edition



 

Omega Pharma CEO: We are doing great

Staff writer |
Omega Pharma NV said any speculation about the future of the company was premature as no decision had yet been taken.

Article continues below






The firm, taken private by chief executive officer Mark Coucke and private equity group Waterland, hired Morgan Stanley to look at strategic options, including a possible sale, one person with direct knowledge of the matter told Reuters.

Bloomberg earlier reported Omega Pharma was considering a sale in a deal that could earn its owners more than $4 billion.

"The rumours about Omega Pharma are premature and one-sided. The business is doing great. The environment changes quickly so you have to investigate your options," Mr. Coucke wrote on Twitter.

"That's why we are looking together with Waterland how Omega Pharma can be even stronger in the future. There is still so much left to build," he added.

Omega Pharma sells prescription-free medicines, healthcare products and over-the-counter (OTC) items such as wart treatments and sun tan lotions.

The fragmented OTC industry is consolidating fast and competition for assets is keen, as illustrated by the high-priced $14.2 billion sale of Merck & Co's care business to Germany's Bayer in May.

Coucke said he did not expect any decision soon. "Don't expect anything in the coming months," he wrote on Twitter.


What to read next

BASF sell omega-3 factory in Norway
World's first Omega 3 chicken goes on sale
Omega Healthcare Investors and Aviv REIT to merge